Search

Search Results

1. Immunophenotypic classification regarding prognosis in peripheral T cell lymphoma, NOS, and nodal T follicular helper T cell lymphoma, angioimmunoblastic-type

   This study aimed to determine the clinicopathological predictive factors of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), and...

   Soyeon Choi, Jae-Cheol Jo, ... Hee Jeong Cha in Annals of Hematology

   Article 30 May 2024
   

2. Update on T-Cell Lymphoma Epidemiology

   Purpose of Review

   T-cell lymphomas (TCLs) are a group of rare subtypes of non-Hodgkin lymphoma derived from mature T-lymphocytes. Recent updates in...

   Jane J. Chen, Franco Castillo Tokumori, ... Jia Ruan in Current Hematologic Malignancy Reports

   Article 07 March 2024

3. What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus

   Cutaneous T-cell lymphomas are a heterogenous group of lymphomas that cause various skin manifestations. Severe pruritus occurs frequently in...

   Georgia Biazus Soares, Joan Guitart, Gil Yosipovitch in American Journal of Clinical Dermatology

   Article 16 November 2023
   

4. Extranodal natural killer/T cell lymphoma of the skeletal muscle

   This case report highlights a case of extranodal NK/T cell lymphoma initially misdiagnosed as myositis, emphasizing the appearance on both MRI and...

   Ettore di Gaeta, Floortje Verspoor, ... Robert Hemke in Skeletal Radiology

   Article Open access 20 April 2024
   

5. News on Peripheral T-cell lymphoma

   Peripheral T‑cell lymphomas (PTCL) are a heterogeneous group of rare lymphoid malignancies. Brentuximab vedotin plus cyclophosphamide, doxorubicin,...

   Alexander Pichler in memo - Magazine of European Medical Oncology

   Article Open access 19 January 2023
   

6. Peripheral T-cell lymphoma mimicking granulomatosis with polyangiitis

   Upper respiratory tract involvement is common in patients with granulomatosis with polyangiitis (GPA), but malignancies should be kept in mind in the...

   Elif Durak Ediboğlu, Dilek Solmaz, ... Servet Akar in Zeitschrift für Rheumatologie

   Article 26 May 2023
   

7. Novel CAR T cell therapies for patients with large B cell lymphoma

   Approximately 60–70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients...

   Hideki Goto, Masahiro Onozawa, Takanori Teshima in International Journal of Hematology

   Article 25 May 2024
   

8. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis

   Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell...

   Mary Jo Lechowicz, Christy Smith, ... Karen Dwyer in International Journal of Hematology

   Article Open access 27 March 2024
   

9. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy

   In recent years, chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the treatment landscape for large B cell lymphoma (LBCL),...

   Samantha El Warrak, Mohamed A. Kharfan-Dabaja, ... Razan Mohty in Bone Marrow Transplantation

   Article 16 December 2023
   

10. Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy

    Chimeric antigen receptor T-cell (CAR-T) therapy is a recent advancement in precision medicine with promising results for patients with relapsed or...

    Nandan Padmanabha, Matthew J. Weinstock, ... Phillip D. Michaels in Journal of Hematopathology

    Article 15 June 2024
    

11. Indolent B-cell lymphoma with t(14;19) investigated from a molecular perspective

    T(14;19) is an unusual but distinct genomic alteration reported in low-grade B-cell lymphomas. This structural rearrangement places BCL3 in...

    Jeremiah X. Karrs, Shivaprasad H. Sathyanarayana, ... Prabhjot Kaur in Journal of Hematopathology

    Article 13 October 2023
    

12. CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma

    Background

    Natural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell...

    Hongwen Li, Wenting Song, ... Mingzhi Zhang in BMC Medicine

    Article Open access 30 August 2023
    

13. Recent advances in CAR T-cell therapy for lymphoma in China

    Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy,...

    Yuxuan Che, **uhua Sun in Clinical and Translational Oncology

    Article Open access 16 April 2023

14. Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma

    Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies,...

    Kenta Hayashino, Keisuke Seike, ... Yoshinobu Maeda in International Journal of Hematology

    Article Open access 13 February 2024
    

15. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment

    CD19 CAR-T (chimeric antigen receptor-T) cell immunotherapy achieves a remission rate of approximately 70% in recurrent and refractory lymphoma...

    Wei-Wei Zheng, Hang Zhou, ... Cai-Wen Duan in Cancer Immunology, Immunotherapy

    Article 14 September 2023
    

16. Neurolymphomatosis as primary presentation of extra-nodal NK/T-cell lymphoma, nasal type

    Neurolymphomatosis (NL) describes an infiltration of cranial and peripheral nerves by lymphoma cells, most frequently in non-Hodgkin B-cell lymphoma....

    Maria Inês Silva, Pedro Santos, ... Cátia Carmona in Neurological Sciences

    Article 12 March 2024
    

17. Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma

    Immunotherapy with programmed cell death 1 ligand 1 (PD-L1) blockade was effective in patients with NK/T-cell lymphoma. In addition to PD-L1,...

    Yajun Li, Kailin Chen, ... Hui Zhou in Leukemia

    Article 23 May 2024
    

18. What Is New in Cutaneous T Cell Lymphoma?

    Purpose of Review

    This review focuses on updates in prognosis, pathogenesis, and treatment of cutaneous T cell lymphoma (CTCL).

    Recent Findings ...

    Sarah Morgenroth, Andrea Roggo, ... Egle Ramelyte in Current Oncology Reports

    Article Open access 24 October 2023
    

19. Initial diagnosis of extranodal NK/T-cell lymphoma in pericardial fluid with concomitant hemophagocytic lymphohistiocytosis (HLH)

    Extranasal natural killer/T-cell lymphoma arising in the heart is rare and typically presents with non-specific clinical symptoms, necessitating a...

    Amani Khasawneh, Georgeann McGuinness, Nicholas Ward in Journal of Hematopathology

    Article 26 December 2023
    

20. CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

    Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell...

    Qiusha Huang, **ao-hui Zhang, Delong Liu in Journal of Hematology & Oncology

    Article Open access 05 March 2023